Evidence-based·Updated November 20, 2026·How we grade evidence

Orforglipron (Foundayo)

MedicationOral GLP-1 medicine (prescription)

Orforglipron (Foundayo) is an FDA-approved once-daily GLP-1 receptor agonist pill for chronic weight management. In two 72-week placebo-controlled trials, the highest dose lowered body weight by about 11% in adults without diabetes and about 10% in adults with type 2 diabetes, compared with about 2% on placebo, and a 52-week trial found it helped people keep off much of the weight they had lost on tirzepatide or semaglutide injections. Stomach and bowel side effects are common, and the label carries a boxed warning about thyroid C-cell tumors.

Taking Orforglipron (Foundayo) with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with obesity, or overweight plus a weight-related condition, whose prescriber recommends a daily oral GLP-1 medicine alongside diet and activity changes

Common dosing range

Set by your prescriber. The label starts at 0.8 mg once daily and steps up at least every 30 days (2.5 mg, then 5.5 mg, and if needed 9 mg, 14.5 mg or 17.2 mg once daily)

When to expect effects

Weight loss builds over months; in the trials, the main result was measured after 72 weeks

Watch out for

Boxed warning: thyroid C-cell tumors were seen in rodents with other GLP-1 drugs, and it must not be used with a personal or family history of medullary thyroid cancer or MEN 2. Nausea, vomiting, diarrhea and constipation are common. It can affect pancreas, gallbladder and kidneys, may cause fetal harm, and can make birth control pills less reliable for 30 days after starting and after each dose increase

What is it

Orforglipron is a prescription weight-management medicine sold as Foundayo tablets by Eli Lilly. The FDA approved it on April 1, 2026 as a new molecular entity (NDA 220934), and the FDA approved an updated label on August 4, 2026. It is a GLP-1 receptor agonist, the same drug class as semaglutide and liraglutide, but it is a small molecule taken by mouth once a day rather than an injected peptide. The Foundayo label approves it, together with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or adults with overweight and at least one weight-related condition. It is not approved for children, and the label says use together with another GLP-1 receptor agonist is not recommended.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have obesity, or overweight with a weight-related condition, and your prescriber recommends a GLP-1 medicine as part of a diet and activity plan
You prefer a daily tablet that does not have to be taken on an empty stomach, and your prescriber agrees it fits your other medicines
You can step the dose up slowly as directed and report stomach or bowel side effects to your prescriber

Probably skip if…

You or a close relative have had medullary thyroid cancer, or you have MEN 2 (contraindicated)
You have had a serious allergic reaction to orforglipron or its ingredients (contraindicated)
You are pregnant or trying to become pregnant, since the label says to stop it when pregnancy is recognized
You have severe gastroparesis or severe liver impairment (Child-Pugh C), where the label says it is not recommended
You already take another GLP-1 receptor agonist, such as semaglutide, liraglutide or dulaglutide

Evidence at a glance

weight loss in adults with obesity without diabetes

Good Evidence
Effect
About 9 percentage points more weight loss than placebo at the highest dose
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Time
Measured at 72 weeks

weight loss in adults with obesity and type 2 diabetes

Good Evidence
Effect
About 7 percentage points more weight loss than placebo at the highest dose
Best fit
Adults with type 2 diabetes and overweight or obesity treated with diet or oral diabetes medicines
Time
Measured at 72 weeks

keeping weight off after stopping tirzepatide or semaglutide injections

Good Evidence
Effect
About 25 to 42 percentage points more of the lost weight kept than with placebo
Best fit
Adults who lost weight on tirzepatide or semaglutide injections, the only groups this trial studied
Time
Measured at 52 weeks

Evidence for 3 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

weight loss in adults with obesity without diabetes

Disease adjunct
Good Evidence

In the double-blind ATTAIN-1 trial, 3,127 adults with obesity (or overweight with a weight-related condition) and no diabetes took orforglipron 6, 12 or 36 mg or placebo once daily for 72 weeks, with diet and activity counseling. Body weight fell by 7.5%, 8.4% and 11.2% on the three doses versus 2.1% on placebo. On the highest dose, 54.6% lost at least 10% of their weight, 36.0% at least 15% and 18.4% at least 20%, compared with 12.9%, 5.9% and 2.8% on placebo. Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol also improved. Side effects led 5.3% to 10.3% to stop, versus 2.7% on placebo. The trial used an investigational formulation; the Foundayo label presents its results as the equivalent Foundayo doses of 5.5, 9 and 17.2 mg. The trial was funded by the manufacturer.

Effect size
About 9 percentage points more weight loss than placebo at the highest dose
Time to effect
Measured at 72 weeks
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Less likely
People who cannot tolerate stomach side effects during dose increases; children were not studied

Bottom line: Daily orforglipron with lifestyle changes led to about 11% weight loss at the top dose over 72 weeks, versus about 2% on placebo.

weight loss in adults with obesity and type 2 diabetes

Disease adjunct
Good Evidence

In the double-blind ATTAIN-2 trial, 1,613 adults with a BMI of 27 or more and type 2 diabetes (HbA1c 7% to 10%, average 8.05%) took orforglipron 6, 12 or 36 mg or placebo once daily for 72 weeks. Body weight fell by 5.1%, 7.0% and 9.6% versus 2.5% on placebo, and HbA1c and other heart and metabolic measures also improved. Stopping because of side effects, mainly stomach-related, was 6.1% to 9.9% on orforglipron versus 4.1% on placebo. People on insulin or other injectable diabetes drugs were excluded. As in ATTAIN-1, the Foundayo label presents these doses of the investigational formulation as 5.5, 9 and 17.2 mg of Foundayo. The trial was funded by the manufacturer.

Effect size
About 7 percentage points more weight loss than placebo at the highest dose
Time to effect
Measured at 72 weeks
Best fit
Adults with type 2 diabetes and overweight or obesity treated with diet or oral diabetes medicines
Less likely
People using insulin, who were not studied in this trial; Foundayo is not approved as a diabetes treatment

Bottom line: In people with type 2 diabetes, orforglipron led to about 10% weight loss at the top dose over 72 weeks, versus about 2.5% on placebo.

keeping weight off after stopping tirzepatide or semaglutide injections

Disease adjunct
Good Evidence

The double-blind ATTAIN-MAINTAIN trial enrolled 376 adults who had already lost weight on tirzepatide (205 people) or semaglutide (171 people) in an earlier study, then switched them to daily orforglipron or placebo for 52 weeks. Among those whose weight had plateaued, people coming from tirzepatide kept an estimated 74.7% of their weight loss on orforglipron versus 49.2% on placebo, and people coming from semaglutide kept 79.3% versus 37.6%. The authors note there was no group that simply stayed on the injection, and the trial lasted only one year. It was funded by the manufacturer.

Effect size
About 25 to 42 percentage points more of the lost weight kept than with placebo
Time to effect
Measured at 52 weeks
Best fit
Adults who lost weight on tirzepatide or semaglutide injections, the only groups this trial studied
Less likely
Anyone hoping it matches continuing the injection, which this trial did not test

Bottom line: In people who had lost weight on tirzepatide or semaglutide, orforglipron kept much more of the lost weight off than placebo over one year; it was not compared with staying on the injection.

How it works

Orforglipron binds to and activates the GLP-1 receptor. GLP-1 is a natural gut hormone that helps regulate appetite, and the label says orforglipron lowers body weight mainly by decreasing food intake, likely through reduced appetite, with more fat lost than lean mass. It also slows stomach emptying, most strongly after the first dose, and when blood sugar is high it boosts insulin release, which is why it can cause low blood sugar in people who also take insulin or a sulfonylurea. Because it is a small molecule, it is absorbed from a tablet without the strict fasting rules some oral peptides need: the label says it can be taken with or without food. It reaches steady levels after about a week and has a half-life of about 29 to 49 hours. It is broken down mainly by the liver enzyme CYP3A4, so medicines that strongly block or speed up CYP3A4 change its levels, and it roughly doubles exposure to the active form of simvastatin.

How to take it

1. Typical dose
Your prescriber sets the dose. The Foundayo label starts at 0.8 mg once daily. After at least 30 days the dose goes up to 2.5 mg, and after at least 30 more days to 5.5 mg. Depending on response and tolerability, it may then be increased to 9 mg, 14.5 mg or 17.2 mg once daily, each step after at least 30 days. The maximum is 17.2 mg once daily, and the label says not to take more than one tablet a day.
2. Higher studied dose
The highest labeled dose is 17.2 mg once daily. With a strong CYP3A4 blocker, the label caps the dose at 9 mg once daily. The main trials used an investigational formulation, reported in the published papers as 6, 12 and 36 mg once daily. The Foundayo label presents the results of that formulation as the equivalent Foundayo doses of 5.5, 9 and 17.2 mg once daily.
3. Timing
Once a day. For a missed dose, the label says to take it as soon as possible and not to double the next dose. If 7 or more doses in a row are missed, your prescriber restarts the dose steps at a lower dose to reduce stomach side effects.
4. With food
With or without food. Swallow the tablet whole; do not break, crush or chew it.
5. Split dosing
Not split; one tablet once daily.
6. How long to try
Long term, as your prescriber decides. The label describes it for maintaining weight reduction long term.

What to track

Nausea, vomiting, diarrhea or constipation, especially in the weeks after each dose increase, and signs of dehydration
Severe stomach pain that may spread to the back, with or without vomiting (possible pancreatitis: seek care)
Pain in the upper right belly, fever or yellowing skin or eyes (possible gallbladder disease)
A lump in the neck, trouble swallowing, shortness of breath or lasting hoarseness
Low blood sugar symptoms if you also take insulin or a sulfonylurea
Fast heartbeat or feeling faint, especially if you take blood pressure medicines
Telling every surgeon or anesthesia team that you take it before any procedure

Bottom line: One tablet a day, with or without food, stepped up slowly by your prescriber; tell every prescriber and surgeon you take it.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Nausea (26% to 35% depending on dose, versus 10% on placebo), constipation, diarrhea and vomiting, most often while the dose is being increasedIndigestion, belly pain, bloating, burping, reflux and gasHeadache and tirednessHair loss (4% to 5% versus 2% on placebo), linked to weight reduction and more common in womenA small rise in heart rate (about 4 to 5 beats per minute on average)

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the Foundayo label says it may cause fetal harm, that weight loss offers no benefit during pregnancy, and that it should be stopped when pregnancy is recognized. There are no adequate studies in pregnant women. In a rabbit dose-finding study, exposures 14 times the human exposure at the highest dose caused external malformations in 2 fetuses, while the main rabbit study, at up to about 6 times that exposure, found no effects on the fetus. The label advises effective contraception, and because the drug slows stomach emptying, people using birth control pills should switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase. A pregnancy registry is planned. Breastfeeding: there are no data on orforglipron in human milk; it passed into rat milk at levels 3 times higher than in blood, and the label says it is not recommended while nursing.

Interactions

Birth control pills and other medicines taken by mouthHigh

Orforglipron slows stomach emptying, which can change how other tablets are absorbed. The label tells people on oral hormonal birth control to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase. Birth control that is not taken by mouth is not expected to be affected.

Strong CYP3A4 blockers (the label names ritonavir as an example)High

These raise orforglipron levels and side-effect risk. The label caps the dose at 9 mg a day with a strong CYP3A4 blocker and says to avoid those that also block the OATP1B transporter, such as ritonavir. Make sure every prescriber knows you take Foundayo.

Strong CYP3A4 inducers (for example carbamazepine)High

The Foundayo label says to avoid strong CYP3A4 inducers with Foundayo, because they lower orforglipron levels, which may make it work less well. In a study, the strong inducer carbamazepine cut orforglipron exposure by 82%. Your prescriber decides whether a change is needed, so talk to them before stopping or changing either medicine.

St. John's wort (Hypericum perforatum)High

The Foundayo label says to avoid strong CYP3A4 inducers because they lower orforglipron levels and may make it work less well (the strong inducer carbamazepine cut exposure by 82%). The FDA classes St. John's wort as a strong CYP3A inducer, although its effect varies by product. It has not been tested with orforglipron. Avoid it unless your prescriber agrees, and talk to your prescriber or pharmacist before changing either one.

Insulin and sulfonylureas (for example glipizide, glimepiride)High

Together they raise the risk of low blood sugar, including severe episodes. In a trial of people with type 2 diabetes, 7% of those also taking a sulfonylurea had low blood sugar, versus 0.5% of those who were not. The label says a lower dose of insulin or sulfonylurea may be needed; your prescriber decides.

Moderate CYP3A4 inducers (for example efavirenz)Moderate

These also lower orforglipron levels: a computer model on the label predicted a 61% drop in exposure with efavirenz. With moderate inducers, the label says to monitor how well Foundayo works and step up the dose as needed. Your prescriber decides whether a change is needed.

SimvastatinModerate

Orforglipron doubled exposure to the active form of simvastatin in a study. The label says not to exceed simvastatin 20 mg once daily together with Foundayo. Ask your prescriber or pharmacist to review your statin dose.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Foundayo (orforglipron) tablets dispensed by a licensed pharmacy on your own prescription
The tablet strength on your label (0.8, 2.5, 5.5, 9, 14.5 or 17.2 mg), which changes as your dose is stepped up
A Medication Guide with each fill, which explains the thyroid tumor warning and the birth control advice
Your pharmacy's interaction check against your other prescriptions, including statins and CYP3A4 medicines

Be skeptical of…

"Oral GLP-1" or "orforglipron" products sold without a prescription, including "research" powders or capsules
Supplements marketed as a "natural GLP-1" or as working like orforglipron
Claims that it works without diet and activity changes, or that weight stays off after stopping
Advice to take more than one tablet a day or to skip the dose steps to lose weight faster

Frequently asked questions

Is orforglipron FDA-approved?⌄

Yes. The FDA approved orforglipron as Foundayo tablets on April 1, 2026, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, together with diet and physical activity. It is a prescription medicine. It is not approved for children, and its label is for weight management, not as a diabetes treatment.

How is it different from semaglutide or tirzepatide injections?⌄

Orforglipron works on the same GLP-1 receptor as semaglutide, but it is a small-molecule tablet taken once a day, with or without food, instead of a weekly injection. In the trials behind the Foundayo label, orforglipron was compared with placebo, not head to head with these injections, so the trials do not show which works better for weight.

Can I take my supplements with orforglipron?⌄

Our interaction database has no supplement pairs for orforglipron yet, and we found no study that tested supplements with it. Because it slows stomach emptying and is broken down by the enzyme CYP3A4, ask your doctor or pharmacist to check every supplement and medicine you take, especially herbal products.

Does it affect birth control pills?⌄

It can. The label says to switch to a non-oral birth control method, or add a barrier method such as condoms, for 30 days after starting Foundayo and for 30 days after each dose increase. Birth control that is not taken by mouth is not expected to be affected. The label also says to stop it if pregnancy is recognized.

What are the most common side effects?⌄

Nausea, constipation, diarrhea, vomiting, indigestion and belly pain were the most common in the trials, mostly mild to moderate and most frequent while the dose was being increased. About 8% of people on it stopped because of side effects, versus 3% on placebo. Severe or lasting stomach pain needs prompt medical attention.

Is it safe to buy orforglipron online?⌄

Foundayo is a prescription medicine dispensed by licensed pharmacies. Products sold online as orforglipron without a prescription, including "research" products, are not FDA-approved Foundayo, and their content and purity are unverified. Talk to your doctor about whether it fits you.

References by claim

weight loss in adults with obesity without diabetes

Wharton et al., 2025 · PubMed (2025) link

weight loss in adults with obesity and type 2 diabetes

Horn et al., 2026 · PubMed (2026) link

keeping weight off after stopping tirzepatide or semaglutide injections

Aronne et al., 2026 · PMC (2026) link

Safety

Foundayo (orforglipron) prescribing information · DailyMed (FDA label) link

Interaction: St. John's wort (Hypericum perforatum)

FDA: Examples of drugs that interact with CYP enzymes and transporter systems · U.S. Food and Drug Administration link

Mueller et al., 2006 · PubMed (2006) link

Track Orforglipron (Foundayo) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 20, 2026·Evidence current as of Nov 20, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.